By far, the most utilized TAV regimens currently under investigation for pancreatic cancer patients are centered around the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine (GVAX)—utilized in 16 studies listed in Table 3 and Table 4 (NCT00389610, NCT03190265, NCT02004262, NCT01417000, NCT00084383, NCT02243371, NCT01896869, NCT00836407, and NCT03161379) [90,91,92,94,95,96,97,98], as well as in Table 1 (NCT01595321, NCT02451982, NCT03006302, and NCT03767582). This evidence concerns the gene CSF2 and neoplasm.